Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models [PDF]
Translational Oncology, 2023 Chemoresistance is a major obstacle in the clinical management of metastatic, castration-resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome chemoresistance and improve clinical outcomes in patients who have failed ...
Lijuan Bai +15 more
doaj +2 more sources
Repurposing of Bromocriptine for Cancer Therapy [PDF]
Frontiers in Pharmacology, 2018 Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.
Ean-Jeong Seo +3 more
doaj +3 more sources
Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases [PDF]
American Journal of Perinatology Reports, 2018 Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy.
Rebecca Simon +2 more
doaj +3 more sources
Bromocriptine and insulin sensitivity in lean and obese subjects [PDF]
Endocrine Connections, 2016 Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated.
L Bahler +6 more
doaj +2 more sources
Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis [PDF]
Cancer Cell International, 2007 Background Prolactinoma is the most frequent pituitary tumor in humans. The dopamine D2 receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and prolactinoma through inhibition of hyperprolactinemia and induction of ...
Huang Mu-Chiou +7 more
doaj +2 more sources
Bromocriptine improves glucose tolerance in obese mice via central dopamine D2 receptor-independent mechanism. [PDF]
PLoS ONEBromocriptine, generally regarded as a dopamine D2 receptor agonist, has been used to treat patients with type 2 diabetes in the USA; however, its mechanisms of action including the receptors that mediate its anti-diabetic effects remain unclear ...
Hiroshi Tsuneki +11 more
doaj +2 more sources
Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes [PDF]
Diabetes, Metabolic Syndrome and Obesity, 2010 Michael A Via1, Himani Chandra2, Takako Araki1, Matthew V Potenza3, Maria Skamagas41Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA; 2Division of Endocrinology, Diabetes and ...
Via MA
doaj +3 more sources
Central Hyperthermia Treated with Bromocriptine [PDF]
Case Reports in Neurological Medicine, 2017 Introduction. Central hyperthermia is common in patients with brain injury. It typically has a rapid onset with high temperatures and marked fluctuations and responds poorly to antibiotics and antipyretics.
P. Natteru +4 more
doaj +2 more sources
Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis
Frontiers in Endocrinology, 2023 ObjectiveBromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical trial. The underlying mechanism contributing to the treatment effect is however unknown.
Yiqun Tang +9 more
doaj +1 more source
Bromocriptine in Parkinsonism [PDF]
BMJ, 1974 Bromocriptine, a drug acting directly upon dopaminergic receptors, has been found to have a significant therapeutic action in a double-blind study of 20 patients with idiopathic Parkinsonism who were already receiving conventional therapy, including levodopa.
D B, Calne +5 more
openaire +2 more sources